1 |
Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, et al. Early intravenous gamma-globulin treatment for Kawasaki disease the nationwide surveys in Japan. J Pediatr 2004;144:496-9
DOI
ScienceOn
|
2 |
Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare;1984
|
3 |
Sundel RP, Burns JC, Baker AS, Newburger JW, Gamma globulin retreatment in Kawasaki disease. J Pediatr 1993;123: 657-9
DOI
ScienceOn
|
4 |
Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80
DOI
ScienceOn
|
5 |
Ayusawa M, Sonobe T, Demara S: Revision of diagnostic guidelines for Kawasaki diseaserthe 5th revised edition). Pediatr Int 2005:47:232-4
DOI
ScienceOn
|
6 |
Onouchi Z, Kawasaki T. Overview of pharmacological treatment of Kawasaki disease. Drugs 1990;58:813-22
DOI
ScienceOn
|
7 |
Nomura Y, Masuda K, Yoshinaga M, Sameshima K, Miyaga K. Patients diagnosed with Kawasaki disease before the fifth day of illness have a higher risk of coronary artery aneurysm. Pediatr Int 2002:44:353-7
DOI
ScienceOn
|
8 |
Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991;33:805-10
DOI
|
9 |
Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr 2004;16:508-14
DOI
ScienceOn
|
10 |
Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 2000;154:694-9
DOI
|
11 |
Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002;140:450-5
DOI
ScienceOn
|
12 |
Nakamura Y, Yashiro M, Uehara R, Watanabe M, Tajimi M, Oki I, et, al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004:46:33-8
DOI
ScienceOn
|
13 |
Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gamma globulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78
DOI
ScienceOn
|
14 |
Yanagawa H, Nakamura Y, Sakata K, Yashiro M. Use of intravenousgarnrna-globulin for Kawasaki disease: effects on cardiac sequelae. Pediatr Cardiol 1997;18:19-23
DOI
ScienceOn
|
15 |
Kim EJ, Hong ME, Lee CW, Oh YG, Kim JD, Yoon HS. The clinical and laboratory features of Kawasaki disease with nonresponsibility to the acute antiinflammatory treatment. J Korean Pediatr Soc 2003:46:500-4
|
16 |
SugaharaY, Ishii M, Muta H, Furui J, Himeno W, Akagi T. The effectiveness and safety of early intravenous immune globulin treatment for Kawasaki disease. 7th International Kawasaki Disease Symposium; December 4-7,2001 Hakone, Japan; Japan Kawasaki Disease Research Center, 2001
|
17 |
Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatrnent in Kawasaki disease. Pediatr Infect Dis J 1998;17:1144-8
DOI
ScienceOn
|
18 |
Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J Allergy 1967;16:178-222
|
19 |
Yanagawa H, Nakimura Y, Yashiro M. The results of 16th nationwide survey of Kawasaki disease in Japan. J Pediatr Practice 2002;65:332-42
|
20 |
Shim SY, Heo MY, Kim HS, Sonh SJ. High-dose intravenous immune globulin retreatment in Kawasaki disease. J Korean Pediatr Soc 2002:45:1273-7
|
21 |
Freeman AF, Shulman ST. Kawasaki disease: summary of the American Heart Association guidelines. Am Fam Physician. 2006;74:1141-8
|
22 |
Newburger JW, Takahashi M, Bums JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315: 341-7
DOI
ScienceOn
|
23 |
Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronaryartery lesions after intravenous gammaglobulin treatment in Kawasaki disease. J Pediatr 2000;137: 177-80
DOI
ScienceOn
|